- Microbion wins Innovation Showcase Award at Advanced Wound Care
Summit USA 2024
BOZEMAN,
Mont. and VANCOUVER,
BC, April 25, 2024 /PRNewswire/ - Microbion
Corporation today announced that the company won the Advanced Wound
Care Summit's Innovation Showcase award. The Innovation Showcase
was designed to give presenters, who were picked by a selection
committee, an opportunity to demonstrate their vision of the future
of wound care, and how their product, technology, or service fits
into it. The presentation was focused on topical pravibismane's
clinical safety and efficacy for the treatment of moderate to
severe diabetic foot ulcer infection (DFI) and future development
plans.
"We would like to thank the selection committee for recognizing
topical pravibismane's innovation as a multimodal therapeutic with
the potential to significantly impact patients' lives and give
health care providers a new therapeutic option that addresses
several unmet needs in the treatment of infected diabetic foot
ulcers," said Karim Lalji,
Microbion's CEO. "We praise the efforts of our fellow presenters
whose technologies also have the potential to impact the lives of
patients."
In a Phase 1b study in patients
with moderate to severe DFI, pravibismane was well-tolerated and
pravibismane treated subjects showed an approximately 3-fold
reduction in ulcer size compared to the placebo group (85% versus
30%). Furthermore, the incidence of diabetic ulcer-related lower
limb amputations was approximately 6-fold lower in the pooled
pravibismane group compared to the placebo group (2.6% versus
15.4%). Topically applied pravibismane has the potential to address
several unmet medical needs for the successful treatment of DFI by
simultaneously treating bacterial biofilm-related infections and
accelerating ulcer size reduction, potentially leading to complete
re-epithelialization and wound closure along with reduction of
reinfection and amputation risks.
The company has recently completed a Phase 2 study assessing the
safety, tolerability, and wound closure efficacy of a higher
concentration and longer, 12-week dosing duration of topical
pravibismane in patients with moderately infected chronic diabetic
foot ulcers.
About Microbion
Microbion is a clinical-stage pharmaceutical company developing
a new class of therapeutic compounds to improve the lives of
patients with rare and serious diseases. Microbion's lead drug
candidate, pravibismane, is the first product in this new class and
has multiple novel modes of action, including potent broad spectrum
anti-infective, antibiofilm, and immuno-modulatory activity,
offering unique potential to address the unmet needs of chronic and
severe health conditions. Topical pravibismane is completing Phase
2 development for the treatment of chronic wounds. Local
pravibismane is in Phase 2 clinical development for orthopedic
infections and inhaled pravibismane is advancing into Phase 1
clinical development for the treatment of chronic lung diseases,
including non-tuberculous mycobacteria (NTM) and cystic
fibrosis-related lung infections. Pravibismane has received backing
from the Cystic Fibrosis Foundation, NIH, US DoD, and CARB-X with
over $20 million in non-dilutive
grants. The FDA has granted pravibismane Orphan Drug, Fast Track,
and Qualified Infectious Disease Product (QIDP) designations.
For more information visit: www.microbioncorp.com.
Safe Harbor Statement
Certain of the statements made in this press release are
forward-looking, such as those, among others, relating to the
success of clinical development of pravibismane and preparation for
potential commercialization. These statements are subject to risks
and uncertainties that could cause actual results and events to
differ materially from those anticipated, including, but not
limited to, risks and uncertainties related to: our ability to
enroll patients in our clinical trials at the pace that we project;
the size and growth of the potential markets for pravibismane or
any future product candidates and our ability to serve those
markets; our ability to obtain and maintain regulatory approval of
pravibismane or any future product candidates; and our expectations
regarding the potential safety, efficacy or clinical utility of
pravibismane or any future product candidates. Actual results or
developments may differ materially from those projected or implied
in these forward-looking statements. Microbion Corporation
disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/microbion-receives-award-at-advanced-wound-care-summit-usas-innovation-showcase-302126822.html
SOURCE Microbion Corporation